ClinicalTrials.gg
Active, not recruitingNCT07794748Updated Nov 12, 2026

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

A Phase 3 interventional study of PG4 Multivalent Vaccine and PG4 Multivalent Vaccine in Pneumococcal Disease, sponsored by Pfizer. Active, not recruiting at 37 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,701
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.

Enrollment
2nd of 57
4,701 · median 570
Started
2026
with 4 others
Phase 3
33 of 75
4 open now
Registered
75th of 75
by date

Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 2nd largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2026, is one of 33 in phase 3, and was the 75th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Pneumococcal Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.

This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines.

The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC.

Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC.

Each participant will take part in the study for approximately 6 months.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults 18 through 49 years of age, who have no history of receiving a pneumococcal vaccine after 5 years of age.

Exclusion criteria

Exclusion Criteria:

Individuals with a history of severe allergic reactions to a vaccine or its components, serious chronic medical disorders, significant psychiatric conditions, known or suspected immunodeficiency, substance abuse issues, asplenia, bleeding diathesis or prolonged bleeding, a history of a prior confirmed invasive pneumococcal infection, and pregnant or breastfeeding females will be excluded from enrollment in the trial.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
4,701 participants (actual)

Study arms

  • Experimental
    PG4 Vaccine Lot 1

    Multivalent Pneumococcal Vaccine

    Biological: PG4 Multivalent Vaccine

  • Experimental
    PG4 Vaccine Lot 2

    Multivalent Pneumococcal Vaccine

    Biological: PG4 Multivalent Vaccine

  • Experimental
    PG4 Vaccine Lot 3

    Multivalent Pneumococcal Vaccine

    Biological: PG4 Multivalent Vaccine

  • Active comparator
    20 Valent Pneumococcal Conjugate Vaccine (20vPnC)

    20 Valent Pneumococcal Conjugate Vaccine

    Biological: 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)

Interventions

  • BiologicalPG4 Multivalent Vaccine

    Multivalent Pneumococcal Vaccine

    Also known as: PG4 lot 1

  • BiologicalPG4 Multivalent Vaccine

    Multivalent Pneumococcal Vaccine

    Also known as: PG4 Lot 2

  • BiologicalPG4 Multivalent Vaccine

    Multivalent Pneumococcal Vaccine

    Also known as: PG4 Lot 3

  • 20 Valent Pneumococcal Conjugate Vaccine

    Also known as: Prevnar 20

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Prespecified Local Reactions Within 7 Days After Vaccination

    Prompted local reactions after each dose

    Time frame: Within 7 days after Vaccination

  2. Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after Vaccination

    Prompted systemic events after each dose

    Time frame: Within 7 days after Vaccination

  3. Percentage of Participants with Adverse Events (AEs)

    AEs occurring from Dose 1 to 1 month after the vaccination

    Time frame: From Vaccination to 1 month after Vaccination

  4. Percentage of Participants with Serious Adverse Events (SAEs)

    SAEs occurring from Dose 1 to 6 months after the vaccination

    Time frame: From Vaccination to 6 months after Vaccination

  5. OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lots

    OPA GMRs between each pair of PG4 vaccine lots at 1 month after vaccination

    Time frame: 1 month after Vaccination

Secondary outcomes

  1. OPA Serotype-specific geometric mean titers (GMT) for PG4 vaccine serotypes

    OPA GMTs at 1 month after vaccination

    Time frame: 1 month after Vaccination

  2. OPA geometric mean fold rise (GMFR) for PG4 vaccine serotypes

    GMFRs in OPA titers from before to 1 month after vaccination

    Time frame: From before vaccination to 1 month after vaccination

  3. Percentages of participants with a ≥4-fold rise in opsonophagocytic activity (OPA) titers

    Percentages of participants with a ≥4-fold rise in OPA titers from before to 1 month after vaccination

    Time frame: From Vaccination to 6 months after Vaccination

  4. Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ)

    Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ) from before vaccination to 1 month after vaccination

    Time frame: From before vaccination to 1 month after vaccination

07

Study locations

37 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 7 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 7 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2027 → Apr 2027 and completion Jun 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartActual
Sep 8, 2026
Primary completionEst.
Apr 26, 2027was Jun 2027
CompletionEst.
Apr 26, 2027was Jun 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Sites
1 site added
Show site
  • DM Clinical Research · Philadelphia, United States
Oct 14, 2026
Primary completion
Jun 7, 2027→Apr 26, 2027
Nov 12, 2026
Study completion
Jun 7, 2027→Apr 26, 2027
Nov 12, 2026
Enrollment
4670 (estimated)→4701 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 7, 2027→Apr 26, 2027
    Study completion Jun 7, 2027→Apr 26, 2027
    Enrollment 4670 (estimated)→4701 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 14, 2026
    1 site added
    Show site
    • DM Clinical Research · Philadelphia, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07794748
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Sep 8, 2026
Primary completion
Apr 26, 2027 (estimated)
Completion
Apr 26, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion